BIO-PATH HOLDINGS, INC.
BPTHDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BP1001 in combination with Ventoclax plus decitabine | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Frequently asked questions
What is in BIO-PATH HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in BIO-PATH HOLDINGS, INC.'s (BPTH) pipeline across Phase 2. Its lead program is BP1001 in combination with Ventoclax plus decitabine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BIO-PATH HOLDINGS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BIO-PATH HOLDINGS, INC. (BPTH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BPTH biotech catalysts?→
Add BPTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BIO-PATH HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.